Side-by-side
| BPC-157 | TB-500 | |
|---|---|---|
| Mechanism | Pentadecapeptide; upregulates VEGF, modulates NO pathway, accelerates tendon and gut-mucosal repair. | Synthetic fragment of Thymosin-β4; drives actin polymerisation and angiogenesis. |
| Half-life | ~4 hours in circulation; stable at gastric pH in preclinical models. | Plasma half-life short; accumulated effect observed over a loading protocol. |
| Dose | 250-500 mcg/day SC, 1-2× daily. | 2-2.5 mg twice weekly SC (loading), then 2 mg/week maintenance. |
| Cycle | 4-6 weeks is the typical research window. | 4-6 weeks loading, followed by a lower maintenance dose. |
| Research context | Strongest preclinical dataset for tendon, ligament, and gut-mucosal repair1. | Myocardial, dermal, and musculoskeletal repair models; multi-functional regenerative profile2. |
| Cost tier | Low per-cycle cost (small daily dose). | Mid per-cycle cost (large loading doses). |
When researchers choose BPC-157 over TB-500, the reasoning is usually tissue-specific. BPC-157's preclinical dataset is densest in tendon-to-bone healing1, ligament repair, and gut-mucosal integrity, which is why it dominates research protocols that target musculoskeletal injury or GI inflammation. Its short half-life means daily or twice-daily subcutaneous dosing, but the per-dose amount is small (250-500 mcg), which keeps the per-cycle cost low.
TB-500 is selected when the repair target is broader or more vascular. The peptide is a fragment of Thymosin-β4, which is a natural actin-sequestering protein implicated in dermal wound healing, myocardial repair, and angiogenesis2. Because circulating half-life is short but cumulative tissue effects are longer, research protocols typically use a twice-weekly loading phase at 2-2.5 mg, then drop to a maintenance dose.
The canonical stack question is whether the two combine productively. In the literature the rationale is complementary: BPC-157 drives localised cytoprotection and VEGF-mediated angiogenesis; TB-500 contributes systemic actin remodelling and cell migration. No head-to-head human trial has compared them, so any "which is better" answer remains context-dependent. For researchers working with a defined tendon or GI endpoint, BPC-157 has the richer preclinical base. For systemic or dermal targets, or when both pathways are relevant, the stack is what the original investigators tended to propose3.
See the full depth on each compound in the BPC-157 mechanism deep-dive and the TB-500 research history.
Frequently asked
Can BPC-157 and TB-500 be stacked?
Which has stronger preclinical data for tendon injury?
What is the typical cycle length for either peptide?
Go deeper
Related comparisons
- Comparison BPC-157 vs Thymosin-α1 BPC-157 versus Thymosin-α1 compared on tissue-repair vs immune-modulation mechanisms, dosing, and research context. Cited research from PubMed.
- Comparison BPC-157 vs LL-37 BPC-157 and LL-37 contrasted: tissue repair vs antimicrobial and immune-modulatory mechanism. Cited research summary from PubMed.
- Comparison TB-500 vs Thymosin-α1 TB-500 and Thymosin-α1 compared: thymic peptide fragments with different targets, tissue repair vs T-cell maturation. Cited research from PubMed.
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID: 22074294
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018. PMID: 29998800
All references verified against PubMed via NCBI E-utilities.